1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Cyclopharm Limited

Cyclopharm Limited

CYC.AX
Cyclopharm LimitedAU flagAustralian Securities Exchange
0.46
AUD
-0.01
- -
57.99MMarket Cap
Cyclopharm Limited
CYC.AX
(Australian Securities Exchange)

Recent

price

0.46

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.26
0.29
0.09
0.2
0.21
0.22
0.26
0.19
0.2
0.21
0.19
0.2
0.25
0.28
0.27
0.15
Revenue per Share
0.01
-0.03
-0.01
-0.01
0.07
0.09
0.01
-0.02
- -
-0.04
-0.08
-0.06
-0.07
-0.05
-0.13
-0.16
Basic EPS, GAAP
-0.15
-0.01
- -
-0.01
- -
- -
-0.03
-0.03
-0.03
-0.01
-0.01
-0.01
-0.02
-0.01
-0.01
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
- -
- -
Dividend per Share
0.41
0.45
0.14
0.28
0.14
0.22
0.23
0.25
0.25
0.33
0.21
0.46
0.37
0.31
0.38
0.2
Book Value per Share
0.3
0.34
0.1
0.2
0.12
0.21
0.19
0.21
0.18
0.27
0.15
0.42
0.34
0.29
0.36
0.22
Tangible Book Value per Share
37
35
122
58
58
56
56
68
68
68
77
90
92
93
103
110
Basic Weighted Avg Shares
9
10
11
12
12
13
14
13
13
14
15
18
23
26
28
17
Sales/Revenue/Turnover
13.2
-0.62
-4.17
-4.71
8.99
16.65
9.8
-13.05
-20.59
-44.5
-57.83
-39.27
-32.88
-38.06
-52.68
-202.58
Operating Margin (%)
- -
1
1
1
- -
- -
- -
- -
1
1
1
1
1
1
1
2
Depreciation Expense
- -
-1
-1
-1
4
5
1
-2
- -
-3
-6
-5
-7
-5
-13
-17
Net Income, GAAP
44.32
- -
- -
- -
- -
- -
44
316.21
129.94
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
4.76
-9.27
-9.72
-6.56
33.75
38.09
5.53
-11.56
-0.26
-20.69
-41.18
-28.47
-28.47
-17.85
-47.87
-103.16
Profit Margin (%)
- -
6
3
2
6
10
7
12
10
16
10
36
29
22
32
17
Working Capital
- -
4
- -
- -
- -
- -
- -
- -
- -
5
5
4
4
4
8
7
LT Debt
14
15
16
15
8
13
12
17
17
23
17
43
37
32
43
27
Total Equity
3.76
- -
- -
- -
- -
- -
6.03
23.71
4.49
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
2.92
- -
- -
- -
- -
- -
6.37
-10.43
-0.25
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
3.05
-6.17
-6.35
-4.73
33.88
47.12
6.34
-10.2
-0.21
-14.71
-31.24
-17.57
-17.46
-14.81
-38.62
-56.26
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.33%
24.13%
-36.55%
Free Cash Flow
1,459.99%
56.86%
116.87%
Net Income, GAAP
794.61%
39.38%
30.48%
Sales/Revenue/Turnover
4.74%
6.09%
-39.46%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
26
2024
- -
- -
- -
- -
28
2025
- -
- -
- -
- -
17

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.05
2024
- -
- -
- -
- -
-0.13
2025
- -
- -
- -
- -
-0.16

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.01
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Senzime AB (publ) (SNZZF)
GPX Medical AB (publ) (GPXMED.ST)
Theralase Technologies Inc. (TLTFF)
Profound Medical Corp. (PROF)
ProSomnus, Inc. (OSAPQ)
Eurobio Scientific S.A. (ALERS.PA)
Business
Cyclopharm Limited is an Australian health technology company specializing in the research, development, manufacture, and sale of medical equipment and radiopharmaceuticals primarily used in functional lung ventilation imaging. Its core product is Technegas, a diagnostic imaging technology used globally for the detection of pulmonary embolism and other respiratory conditions such as asthma, COPD, lung cancer, pulmonary hypertension, and long COVID. The company also offers a range of associated consumables and diagnostic kits, alongside a molecular imaging segment producing radiopharmaceuticals for detecting cancer, neurological disorders, and cardiac diseases. Cyclopharm operates through direct sales and third-party distribution partnerships across the Asia Pacific, Europe, Canada, and the United States. Founded in 1990 and headquartered in Sydney, Australia, Cyclopharm has expanded its footprint with regulatory approvals and extensive sales and service networks worldwide. In recent strategic developments, Cyclopharm secured a major three-year contract to deploy Technegas in up to 169 nuclear medicine departments within the Hospital Corporation of America network, marking a significant expansion in the U.S. market. The company also achieved the maximum patent extension of five years for its Technegas technology in the United States, reinforcing its competitive position. Cyclopharm completed a successful $20 million capital raising in 2024 to support U.S. growth initiatives and has launched clinical trials targeting expanded indications of Technegas beyond pulmonary embolism, including chronic respiratory diseases. Operationally, the company renewed regulatory certifications under new MDR and MDSAP standards and reshaped its board to enhance strategic leadership in preparation for growth. Cyclopharm continues to invest in expanding its clinical applications and third-party distribution channels, driving revenue growth with a strong focus on the U.S. and global markets.